Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual case insights shaping a new protocol for post-menopausal hirsutism.

JCEM case reports·2026
Same author

Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Visualizing pathology: The development of a narrated video autopsy for medical students.

Academic pathology·2026
Same author

Prednisolone Once Daily vs Hydrocortisone Thrice Daily in Hypoadrenalism: A Randomized Clinical Trial.

JAMA network open·2026
Same author

Cardiovascular risk profile of low-dose prednisolone and its effect on the quality of life in patients with adrenal insufficiency: the HYPER-AID observational study.

Endocrine connections·2026
Same author

Safety and effectiveness of rivaroxaban thromboprophylaxis in adrenocorticotropic hormone-dependent Cushing syndrome.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Peptides: FDA appointed advisory committee criticised for conflicts of interest.

BMJ (Clinical research ed.)·2026
Same journal

Hantavirus outbreak linked to cruise ship is over, say officials.

BMJ (Clinical research ed.)·2026
Same journal

BMA recommends that 16 and 17 year olds get access to cross sex hormones.

BMJ (Clinical research ed.)·2026
Same journal

Andy Burnham could apply lessons from Manchester to create a healthier Britain with a stronger economy.

BMJ (Clinical research ed.)·2026
Same journal

Uganda confirms Marburg case as Ebola outbreak continues.

BMJ (Clinical research ed.)·2026
Same journal

Australia increases penalties for social media companies to enforce under 16s ban.

BMJ (Clinical research ed.)·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

Intranasal Administration of CNS Therapeutics to Awake Mice
07:15

Intranasal Administration of CNS Therapeutics to Awake Mice

Published on: April 8, 2013

New drugs for hyponatraemia

Anjali Amin, Karim Meeran

    BMJ (Clinical Research Ed.)
    |November 17, 2010
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Orthotopic Kidney Auto-Transplantation in a Porcine Model Using 24 Hours Organ Preservation And Continuous Telemetry
    07:58

    Orthotopic Kidney Auto-Transplantation in a Porcine Model Using 24 Hours Organ Preservation And Continuous Telemetry

    Published on: August 21, 2020

    Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model
    05:09

    Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model

    Published on: April 28, 2023

    Related Experiment Videos

    Last Updated: Jun 6, 2026

    Intranasal Administration of CNS Therapeutics to Awake Mice
    07:15

    Intranasal Administration of CNS Therapeutics to Awake Mice

    Published on: April 8, 2013

    Orthotopic Kidney Auto-Transplantation in a Porcine Model Using 24 Hours Organ Preservation And Continuous Telemetry
    07:58

    Orthotopic Kidney Auto-Transplantation in a Porcine Model Using 24 Hours Organ Preservation And Continuous Telemetry

    Published on: August 21, 2020

    Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model
    05:09

    Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model

    Published on: April 28, 2023